Neuroendocrine tumors and somatostatin: imaging techniques

Area of Science:

• Nuclear Medicine
• Oncology
• Endocrinology

Background:

• Somatostatin receptor subtypes 2 (SSTR2) and SSTR5 are expressed in various tumors and metastases.
• Radiolabeled somatostatin analogs, such as 111In-pentetreotide, can visualize these SSTR-expressing lesions in vivo.

Purpose of the Study:

• To evaluate the diagnostic utility and sensitivity of 111In-pentetreotide scintigraphy for detecting a range of neuroendocrine tumors and other lesions.
• To compare its efficacy with other imaging modalities like 123I-MIBG scintigraphy for specific tumor types.

Main Methods:

• Administration of 111In-pentetreotide, a radiolabeled octapeptide somatostatin analog.
• Scintigraphic imaging to visualize tumors and metastases expressing SSTR2 or SSTR5.

Main Results:

• High sensitivity (86-95%) for carcinoid tumors.
• Variable sensitivity for other neuroendocrine tumors (75-100% for gastrinomas, VIPomas, glucagonomas; 50-60% for insulinomas).
• Complementary role in staging malignant pheochromocytomas and detecting extra-adrenal tumors; effective for pituitary adenomas but not microprolactinomas or some ACTH-secreting microadenomas.

Conclusions:

• 111In-pentetreotide scintigraphy is a valuable tool for visualizing SSTR-expressing tumors, with varying sensitivity depending on tumor type.
• It plays a crucial role in diagnosing and staging neuroendocrine tumors, including carcinoids, pituitary adenomas, and pheochromocytomas.
• Its utility is particularly noted for extra-pituitary ACTH-secreting tumors and occult lesions.